Cited by 1,816Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesHIV, Drug Use, Sexual Risk

The DOI matches its Crossref record; 74 of the 76 references it cites were found in a registry or an index.

Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.

Open access

Sordo, Luis, Barrio, Gregorio, Bravo, Maria J, Indave, B Iciar, Degenhardt, Louisa, Wiessing, Lucas, Ferri, Marica, Pastor-Barriuso, Roberto·2017·BMJ

DOI 10.1136/bmj.j1550PMC PMC5421454

Open this paper in CoChat — free account Open PDF

Abstract

Objective To compare the risk for all cause and overdose mortality in people with opioid dependence during and after substitution treatment with methadone or buprenorphine and to characterise trends in risk of mortality after initiation and cessation of treatment. Design Systematic review and meta-analysis. Data sources Medline, Embase, PsycINFO, and LILACS to September 2016. Study selection Prospective or retrospective cohort studies in people with opioid dependence that reported deaths from all causes or overdose during follow-up periods in and out of opioid substitution treatment with methadone or buprenorphine. Data extraction and synthesis Two independent reviewers performed data extraction and assessed study quality. Mortality rates in and out of treatment were jointly combined across methadone or buprenorphine cohorts by using multivariate random effects meta-analysis. Results There were 19 eligible cohorts, following 122 885 people treated with methadone over 1.3-13.9 years and 15 831 people treated with buprenorphine over 1.1-4.5 years. Pooled all cause mortality rates were 11.3 and 36.1 per 1000 person years in and out of methadone treatment (unadjusted out-to-in rate ratio 3.20, 95% confidence interval 2.65 to 3.86) and reduced to 4.3 and 9.5 in and out of buprenorphine treatment (2.20, 1.34 to 3.61). In pooled trend analysis, all cause mortality dropped sharply over the first four weeks of methadone treatment and decreased gradually two weeks after leaving treatment. All cause mortality remained stable during induction and remaining time on buprenorphine treatment. Overdose mortality evolved similarly, with pooled overdose mortality rates of 2.6 and 12.7 per 1000 person years in and out of methadone treatment (unadjusted out-to-in rate ratio 4.80, 2.90 to 7.96) and 1.4 and 4.6 in and out of buprenorphine treatment. Conclusions Retention in methadone and buprenorphine treatment is associated with substantial reductions in the risk for all cause and overdose mortality in people dependent on opioids. The induction phase onto methadone treatment and the time immediately after leaving treatment with both drugs are periods of particularly increased mortality risk, which should be dealt with by both public health and clinical strategies to mitigate such risk. These findings are potentially important, but further research must be conducted to properly account for potential confounding and selection bias in comparisons of mortality risk between opioid substitution treatments, as well as throughout periods in and out of each treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/bmj.j1550

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Untitled work
(2014) · Medical Entomology and Zoology · Cited by 17,633
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Marginal Structural Models and Causal Inference in Epidemiology
Robins, J. M., Hernán, M. Á., & Brumback, B. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00011 · Cited by 5,581
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C. L., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,312
Increases in drug and opioid-involved overdose deaths – United States, 2010-2015
Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm655051e1 · Cited by 2,194
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209.pub2 · Cited by 1,654

Flagged first, then by citations

Show all 76 references

2 of the 76 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

[15]Degenhardt L, Calabria B, Nelson P, et al, and Global Burden of Disease Mental Disorders and Illicit Drug Use Expert group. Methodology used in a systematic review of evidence on the prevalence of amphetamine use and dependence. 2009. Sydney, National Drug and Alcohol Research Centre, University of NSW. Illicit drugs discussion paper No.13.

Sorted by citations

Items 401–500 of 1,000

The Effect of Naloxone Access Laws on Fatal Synthetic Opioid Overdose Fatality Rates
Tabatabai, M., Cooper, R. L., Wilus, D. M., Edgerton, R. D., Ramesh, A., MacMaster, S. A., Patel, P. N., & Singh, K. P. (2023) · Journal of Primary Care & Community Health · doi:10.1177/21501319221147246 · Cited by 27
State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements
Silwal, A., Talbert, J., Bohler, R. M., Kelsch, J., Cook, C., Blevins, D., Gallivan, M., Hunt, T., Hatcher, S. M., Parks, C. L., et al. (2023) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2023.100164 · Cited by 26
“Buprenorphine is an underutilized evidence-based medication treatment for opioid use disorder (MOUD) that reduces mortality by at least 50% (Santo et al., 2021; Sordo et al., 2017; Watts et al., 2022).”
Background
Opportunities for pharmacist prescriptive authority of buprenorphine following passage of the Mainstreaming Addiction Treatment (MAT) Act
Adams, J. L., Chopski, N. L., & Adams, A. J. (2023) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.06.001 · Cited by 26
Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey
Kouyoumdjian, F. G., Patel, A., To, M. J., Kiefer, L., & Regenstreif, L. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192431 · Cited by 28
How Clinicians Caring for Youth Can Address the Opioid-Related Overdose Crisis
Hadland, S. E. (2019) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2019.05.008 · Cited by 26
‘Communities are attempting to tackle the crisis’: a scoping review on community plans to prevent and reduce opioid-related harms
Leece, P., Khorasheh, T., Paul, N., Keller-Olaman, S., Massarella, S., Caldwell, J., Parkinson, M., Strıke, C., Taha, S. A., Penney, G., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028583 · Cited by 26
Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials
van Santen, D. K., Lodi, S., Dietze, P., van den Boom, W., Hayashi, K., Dong, H., Cui, Z., Maher, L., Hickman, M., Boyd, A. C., et al. (2023) · Addiction · doi:10.1111/add.16147 · Cited by 25
Mobile treatment for opioid use disorder: Implementation of community-based, same-day medication access interventions
Chatterjee, A., Baker, T. J., Rudorf, M., Walt, G., Stotz, C., Martin, A., Kinnard, E. N., McAlearney, A. S., Bosak, J., Medley, B., et al. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209272 · Cited by 26
Medications for Opioid Use Disorder in County Jails — Outcomes after Release
Friedmann, P. D., Wilson, D., Stopka, T. J., Bernson, D., Pivovarova, E., Ferguson, W. J., Hoskinson, R. A., Rottapel, R. E., Bovell-Ammon, B. J., Gaba, A., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmsa2415987 · Cited by 25
Methadone Maintenance Treatment for Older Adults: Cost and Logistical Considerations
Cotton, B. P., Bryson, W. C., & BRUCE, M. L. (2017) · Psychiatric Services · doi:10.1176/appi.ps.201700137 · Cited by 25
Do interruptions to the continuity of methadone maintenance treatment in specialist addiction settings increase the risk of drug‐related poisoning deaths? A retrospective cohort study
Durand, L., O’Driscoll, D., Boland, F., Keenan, E., Ryan, B. K., Barry, J., Bennett, K., Fahey, T. P., & Cousins, G. (2020) · Addiction · doi:10.1111/add.15004 · Cited by 25
“1 deaths/1000 person-years) were identified as the highest risk periods for mortality across cohorts [4].”
BackgroundInfluential
Methadone maintenance treatment is swapping one drug for another, and that's why it works: Towards a treatment-based critique of the war on drugs
Frank, D. (2020) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2020.102844 · Cited by 25
“Although MMT is widely recognized as one of the best means of reducing risk of overdose (Schwartz et al., 2013; Sordo et al., 2017), in order to meet its tremendous potential, we must recognize that its use and benefits are intrinsically linked to the larger context of criminalization.”
Background
Trending the evidence on opioid use disorder (OUD) continuum of care among rural American Indian/Alaskan Native (AI/AN) tribes: A systematic scoping review
Mpofu, E., Ingman, S. R., Matthews-Juarez, P., Rivera-Torres, S., & Juárez, P. D. (2020) · Addictive Behaviors · doi:10.1016/j.addbeh.2020.106743 · Cited by 28
The effect of needle and syringe program and opioid agonist therapy on the risk of HIV, hepatitis B and C virus infection for people who inject drugs in Amsterdam, the Netherlands: findings from an emulated target trial
van Santen, D. K., Boyd, A. C., Matser, A. A., Maher, L., Hickman, M., Lodi, S., & Prins, M. (2021) · Addiction · doi:10.1111/add.15503 · Cited by 25
Association between availability of medications for opioid use disorder in specialty treatment and use of medications among patients: A state-level trends analysis
Solomon, K. T., Bandara, S. N., Reynolds, I. S., Krawczyk, N., Saloner, B. K., Stuart, E. A., & Connolly, E. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108424 · Cited by 25
Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV
Wyse, J. J. B., McGinnis, K. A., Edelman, E. J., Gordon, A. J., Manhapra, A., Fiellin, D. A., Moore, B. A., Korthuis, P. T., Kennedy, A. J., Oldfield, B. J., et al. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03452-0 · Cited by 25
Thematic Analysis of Reddit Content About Buprenorphine-naloxone Using Manual Annotation and Natural Language Processing Techniques
Graves, R. L., Perrone, J., Al-Garadi, M. A., Yang, Y., Love, J. S., O’Connor, K., Gonzalez‐Hernandez, G., & Sarker, A. (2021) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000940 · Cited by 25
Opioid agonist treatment initiation and linkage for hospitalized patients seen by a substance use disorder consultation service
Nordeck, C. D., Welsh, C., Schwartz, R. P., Mitchell, S. G., O’Grady, K. E., & Gryczynski, J. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100031 · Cited by 25
A mixed methods study of provider factors in buprenorphine treatment retention
Gertner, A. K., Clare, H. M., Powell, B. J., Gilbert, A. R., Jones, H. E., Silberman, P., Shea, C. M., & Domino, M. E. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103715 · Cited by 25
Buprenorphine Waiver Attitudes Among Primary Care Providers
Lai, B., Croghan, I. T., & Ebbert, J. O. (2022) · Journal of Primary Care & Community Health · doi:10.1177/21501319221112272 · Cited by 25
“The survey assessed 4 domains: (1) attitudes on the effectiveness of MOUD and toward the removal of mandatory training requirements to prescribe buprenorphine; (2) current knowledge about buprenorphine and MOUD; (3) current practice patterns related to screening for and treating OUD; and (4) attitudes toward prescribi…”
Background
Caring for Our Patients With Opioid Use Disorder in the Perioperative Period: A Guide for the Anesthesiologist
Barreveld, A. M., Mendelson, A. M., Deiling, B. L., Armstrong, C. A., Viscusi, E. R., & Kohan, L. R. (2023) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006280 · Cited by 25
Cause-specific mortality of patients with severe chronic pain referred to a multidisciplinary pain clinic: a cohort register-linkage study
Vægter, H. B., Støten, M., Silseth, S. L., Erlangsen, A., Handberg, G., Søndergaard, S. R., & Stenager, E. N. (2018) · Scandinavian Journal of Pain · doi:10.1515/sjpain-2018-0094 · Cited by 24
“cessation of opioids, thus reducing the mortality rate [30].”
Background
Opioid Detoxification in Pregnancy: Systematic Review and Meta-Analysis of Perinatal Outcomes
Wang, M. J., Kuper, S. G., Sims, B., Paddock, C. S., Dantzler, J., Muir, S., & Harper, L. M. (2018) · American Journal of Perinatology · doi:10.1055/s-0038-1670680 · Cited by 25
The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: A randomized trial
Jarvis, B. P., Holtyn, A. F., DeFulio, A., Koffarnus, M. N., Leoutsakos, J., Umbricht, A., Fingerhood, M., Bigelow, G. E., & Silverman, K. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.12.026 · Cited by 25
Public Health Interventions and Overdose-Related Outcomes Among Persons With Opioid Use Disorder
Nataraj, N., Rikard, S. M., Zhang, K., Jiang, X., Guy, G. P., Rice, K., Mattson, C. L., Gladden, R. M., Mustaquim, D., Illg, Z. N., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.4617 · Cited by 24
Trauma treatment for veterans in buprenorphine maintenance treatment for opioid use disorder
Meshberg‐Cohen, S., Black, A. C., DeViva, J. C., Petrakis, I. L., & Rosen, M. I. (2018) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.09.010 · Cited by 24
Buprenorphine treatment for opioid use disorder: recent progress
Parida, S., Carroll, K. M., Petrakis, I. L., & Sofuoglu, M. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1635454 · Cited by 23
“First, the first 4 weeks after treatment drop-out is a particularly high-risk period for overdose risk [27].”
Background
Emergency Department Initiation of Buprenorphine for Opioid Use Disorder: Current Status, and Future Potential
Fox, L., & Nelson, L. S. (2019) · CNS Drugs · doi:10.1007/s40263-019-00667-7 · Cited by 24
Long-term treatment retention in West Virginia's comprehensive opioid addiction treatment (COAT) program
Lander, L. R., Zheng, W., Hustead, J. D., Mahoney, J. J., Berry, J. H., Marshalek, P. J., & Winstanley, E. L. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116712 · Cited by 24
“As the opioid overdose death rate has continued to climb every year in West Virginia, retention in treatment has become increasingly critical as retention in MOUD is associated reduced overdose rates [17,25].”
Background
The relationship between opioid agonist therapy satisfaction and fentanyl exposure in a Canadian setting
Mackay, L., Kerr, T. H., Fairbairn, N. S., Grant, C. C., Milloy, M., & Hayashi, K. (2021) · Addiction Science & Clinical Practice · doi:10.1186/s13722-021-00234-w · Cited by 24
The relationship between crystal methamphetamine use and methadone retention in a prospective cohort of people who use drugs
Mackay, L., Bach, P., Milloy, M., Cui, Z., Kerr, T. H., & Hayashi, K. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108844 · Cited by 27
Long-acting buprenorphine injectables: Opportunity to improve opioid use disorder treatment among rural populations
Lofwall, M. R., & Fanucchi, L. C. (2021) · Preventive Medicine · doi:10.1016/j.ypmed.2021.106756 · Cited by 24
Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence
Wyse, J. J. B., Morasco, B. J., Dougherty, J., Edwards, B., Kansagara, D. L., Gordon, A. J., Korthuis, P. T., Tuepker, A., Lindner, S., Mackey, K., et al. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108923 · Cited by 24
Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients’ and prescribers’ experiences with changes in unsupervised dosing
Corace, K., Suschinsky, K. D., Wyman, J., Leece, P., Cragg, S. E., Konefal, S., Pana, P., Barrass, S., Porath, A. J., & Hutton, B. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103573 · Cited by 24
HIV clinic‐based extended‐release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non‐blinded, randomized non‐inferiority trial
Korthuis, P. T., Cook, R., Lum, P. J., Waddell, E. N., Tookes, H., Vergara‐Rodriguez, P., Kunkel, L. E., Lucas, G. M., Rodriguez, A. E., Bielavitz, S., et al. (2022) · Addiction · doi:10.1111/add.15836 · Cited by 25
Sleep Deficiency and Opioid Use Disorder
Langstengel, J., & Yaggi, H. K. (2022) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.05.001 · Cited by 26
A predictive risk model for nonfatal opioid overdose in a statewide population of buprenorphine patients
Chang, H., Krawczyk, N., Schneider, K. E., Ferris, L. M., Eisenberg, M. D., Richards, T. M., Lyons, B. C., Jackson, K., Weiner, J. P., & Saloner, B. K. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.04.016 · Cited by 25
“Under current regulations, buprenorphine can be prescribed for OUD by office-based clinicians with a federal prescribing waiver.”
BackgroundInfluential
Increasing Access to Medications for Opioid Use Disorder and Complementary and Integrative Health Services in Primary Care
Chang, E. T., Oberman, R. S., Cohen, A. N., Taylor, S. L., Gumm, E., Mardian, A. S., Toy, S., Revote, A., Lewkowitz, B., & Yano, E. M. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06255-6 · Cited by 24
Piloting a Hospital-Based Rapid Methadone Initiation Protocol for Fentanyl
Liu, P., Chan, B., Sokolski, E., Patten, A., & Englander, H. L. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001324 · Cited by 23
The Language of Stigma and Addiction
Wakeman, S. E. (2019) · Springer eBooks · doi:10.1007/978-3-030-02580-9_5 · Cited by 23
One-Year Mortality and Associated Factors in Patients Receiving Out-of-Hospital Naloxone for Presumed Opioid Overdose
Ashburn, N. P., Ryder, C. W., Angi, R. M., Snavely, A. C., Nelson, R. D., Bozeman, W. P., McGinnis, H. D., Winslow, J., & Stopyra, J. P. (2020) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2019.11.022 · Cited by 23
Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic
Miles, J., Howell, J., Sheridan, D., Braucht, G. S., & Mericle, A. A. (2020) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2020.1719410 · Cited by 23
“following MOUD initiation (51), and upon MOUD discontinuation (52), and relapse too often results in premature mortality (16).”
Background
Neurocognitive functions in patients on buprenorphine maintenance for opioid dependence: A comparative study with three matched control groups
Saroj, R., Ghosh, A., Subodh, B. N., Nehra, R., Mahintamani, T., Rana, D. K., & Basu, D. (2020) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2020.102181 · Cited by 23
It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment
Stewart, R. E., Wolk, C. B., Neimark, G. B., Vyas, R., Young, J., Tjoa, C., Kampman, K. M., Jones, D. T., & Mandell, D. S. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.108176 · Cited by 23
“A large and growing body of evidence supports medications for opioid use disorder (MOUD) as the most effective treatment (Sordo et al., 2017).”
Background
Development and implementation of a physician-pharmacist collaborative practice model for provision and management of buprenorphine/naloxone
Mailloux, L. M., Haas, M. T., Larew, J., & DeJongh, B. M. (2021) · Mental Health Clinician · doi:10.9740/mhc.2021.01.035 · Cited by 23
Death after emergency department visits for opioid overdose in British Columbia: a retrospective cohort analysis
Moe, J., Chong, M., Zhao, B., Scheuermeyer, F. X., Purssell, R. A., & Slaunwhite, A. (2021) · CMAJ Open · doi:10.9778/cmajo.20200169 · Cited by 23
Design of CLARO (Collaboration Leading to Addiction Treatment and Recovery from other Stresses): A randomized trial of collaborative care for opioid use disorder and co-occurring depression and/or posttraumatic stress disorder
Meredith, L. S., Komaromy, M. S., Cefalu, M. S., Murray-Krezan, C. M., Page, K., Osilla, K. C., Dopp, A. R., Leamon, I. M., Tarhuni, L., Hindmarch, G., et al. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106354 · Cited by 23
The Impact of Current Opioid Agonist Therapy on Hepatitis C Virus Treatment Initiation Among People Who Use Drugs From the Direct-acting Antiviral (DAA) Era: A Population-Based Study
Bartlett, S. R., Wong, S., Yu, A., Pearce, M., MacIsaac, J. L., Nouch, S., Adu, P., Wilton, J., Samji, H., Clementi, E., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab546 · Cited by 23
A cohort study examining the relationship among housing status, patient characteristics, and retention among individuals enrolled in low-barrier-to-treatment-access methadone maintenance treatment
Gazzola, M. G., Carmichael, I. D., Madden, L. M., Dasgupta, N., Beitel, M., Zheng, X., Eggert, K. F., Farnum, S. O., & Barry, D. T. (2022) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2022.108753 · Cited by 23
Use of Cannabis as a Harm Reduction Strategy Among People Who Use Drugs: A Cohort Study
Mok, J., Milloy, M., Grant, C. C., Lake, S., DeBeck, K., Hayashi, K., Kerr, T. H., & Socias, M. E. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0229 · Cited by 24
“…including methadone and buprenorphine/naloxone, have been found to be effective in decreasing unregulated opioid use and overdose risk among people with opioid use disorder (OUD), 6,7 implementation of these evidence-based interventions remains insufﬁcient, with substantial geographical variation.”
Multidimensional assessment of access to medications for opioid use disorder across urban and rural communities: A scoping review
Bommersbach, T. J., Justen, M., Bunting, A. M., Funaro, M. C., Winstanley, E. L., & Joudrey, P. J. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103931 · Cited by 22
Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder
Christine, P. J., Larochelle, M. R., Lin, L. A., McBride, J. P., & Tipirneni, R. (2023) · JAMA Health Forum · doi:10.1001/jamahealthforum.2023.3549 · Cited by 23
Cost of provision of opioid substitution therapy provision in Tijuana, Mexico
Burgos, J. L., Cepeda, J., Kahn, J. G., Mittal, M. L., Meza, E., Lazos, R. R. P., Vargas, P. C., Vickerman, P. T., Strathdee, S. A., & Martin, N. K. (2018) · Harm Reduction Journal · doi:10.1186/s12954-018-0234-x · Cited by 23
“Previous studies have found that poor methadone retention has been associated with relapse [39], criminal behavior [40], and overdose [11].”
Background
Low levels of initiation, engagement, and retention in substance use disorder treatment including pharmacotherapy among HIV-infected and uninfected veterans
Kraemer, K. L., McGinnis, K. A., Fiellin, D. A., Skanderson, M., Gordon, A. J., Robbins, J. L., Zickmund, S. L., BRYANT, K. J., & Korthuis, P. T. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.05.007 · Cited by 23
Canada's hidden opioid crisis: the health care system's inability to manage high-dose opioid patients: Fallout from the 2017 Canadian opioid guidelines.
Clarke, H. A., Bao, J., Weinrib, A., Dubin, R. E., & Kahan, M. (2019) · PubMed Central · Cited by 23
Opioid agonist treatment scale-up and the initiation of injection drug use: A dynamic modeling analysis
Marks, C., Bórquez, A., Jain, S., Sun, X., Strathdee, S. A., Garfein, R. S., Milloy, M., DeBeck, K., Cepeda, J., Werb, D., et al. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002973 · Cited by 23
“PWID currently enrolled in OAT are at a decreased risk of overdose, RROATov [58].”
BackgroundInfluential
Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
Flam-Ross, J. M., Marsh, E., Weitz, M., Savinkina, A., Schackman, B. R., Wang, J., Madushani, R. W. M. A., Morgan, J. R., Barocas, J. A., Walley, A. Y., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.29583 · Cited by 21
High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio
Accurso, A. J., Lee, J. D., & McNeely, J. (2017) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.10.002 · Cited by 22
Correlates of Non-fatal, Opioid Overdose among Women Who Use Opioids in Dar es Salaam, Tanzania
Saleem, H. T., Likindikoki, S. L., Nonyane, B. A. S., Nkya, I. H., Zhang, L., Mbwambo, J. K. K., & Latkin, C. A. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108419 · Cited by 22
“Previous research in other settings has demonstrated an increased risk of non-fatal and fatal opioid overdose during periods immediately following cessation of opioid-related detoxification or treatment programs (Rafful et al., 2018; Sordo et al., 2017).”
Background
HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial
Korthuis, P. T., King, C. A., Cook, R., Khuyen, T. T., Kunkel, L. E., Bart, G. B., Nguyen, T. D., Thuy, D. T., Bielavitz, S., Nguyen, D. B., et al. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(20)30302-7 · Cited by 23
Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder
Nayak, S. M., Huhn, A. S., Bergeria, C. L., Strain, E. C., & Dunn, K. E. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108649 · Cited by 24
New and Emerging Opioid Overdose Risk Factors
Foglia, R., Kline, A., & Cooperman, N. A. (2021) · Current Addiction Reports · doi:10.1007/s40429-021-00368-6 · Cited by 22
Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012–2018
Krebs, E., Homayra, F., Min, J. E., MacDonald, S., Gold, L., Carter, C., & Nosyk, B. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108799 · Cited by 22
Socioeconomic correlates of incident and fatal opioid overdose among Swedish people with opioid use disorder
Dahlman, D., Ohlsson, H., Edwards, A. C., Sundquist, J., Håkansson, A., & Sundquist, K. (2021) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-021-00409-3 · Cited by 22
“Retention in OST is associated with reduction of overdose mortality and morbidity [42], but due to limitations of the registers used we did not have access to information regarding OST.”
Background
Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients—A Critical Review
Soyka, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.718811 · Cited by 22
Long-term treatment retention of an emergency department initiated medication for opioid use disorder program
Reuter, Q. R., Santos, A. M. R., McKinnon, J., Gothard, D., Jouriles, N. J., & Seaberg, D. C. (2022) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2022.02.041 · Cited by 22
Cannabidiol Effect on Cue-Induced Craving for Individuals with Opioid Use Disorder Treated with Buprenorphine: A Small Proof-of-Concept Open-Label Study
Suzuki, J., Martin, B., Prostko, S., Chai, P. R., & Weiss, R. D. (2022) · Integrative Medicine Reports · doi:10.1089/imr.2022.0070 · Cited by 22
Correlates of recent overdose among people who inject drugs in the San Diego/Tijuana border region
Bailey, K., Abramovitz, D. A., Patterson, T. L., Vera, A., Vera, C. F., Rangel, M. G., Friedman, J. R., Davidson, P. J., Bourgois, P. I., & Strathdee, S. A. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109644 · Cited by 22
Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder
Kiluk, B. D., Kleykamp, B. A., Comer, S. D., Griffiths, R. R., Huhn, A. S., Johnson, M. W., Kampman, K. M., Pravetoni, M., Preston, K. L., Vandrey, R. G., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.4020 · Cited by 23
Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials
Baxley, C., Borsari, B. E., Reavis, J. V., Manuel, J. K., Herbst, E. D., Becker, W. C., Pennington, D., Batki, S. L., & Seal, K. H. (2022) · Addictive Behaviors · doi:10.1016/j.addbeh.2022.107589 · Cited by 22
Baseline characteristics of people experiencing homelessness with a recent drug overdose in the PHOENIx pilot randomised controlled trial
Lowrie, R., McPherson, A., Mair, F. S., Stock, K., Jones, C. E., Maguire, D., Paudyal, V., Duncan, C., Blair, B., Lombard, C., et al. (2023) · Harm Reduction Journal · doi:10.1186/s12954-023-00771-4 · Cited by 20
“In terms of established interventions, OST is proven to reduce all cause and overdose mortality in people dependent on street opioids [21].”
BackgroundInfluential
More beds are not the answer: transforming detoxification units into medication induction centers to address the opioid epidemic
Friedmann, P. D., & Suzuki, J. (2017) · Addiction Science & Clinical Practice · doi:10.1186/s13722-017-0092-y · Cited by 22
“The premature discontinuation of pharmacotherapy is especially troubling given the substantial increase in overdose mortality immediately after cessation of effective opioid agonist treatment [5].”
Background
Revising our attitudes towards agonist medications and their diversion in a time of pandemic
del Pozo, B., & Rich, J. D. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.108139 · Cited by 22
The Howard Street Method: A Community Pharmacy-led Low Dose Overlap Buprenorphine Initiation Protocol for Individuals Using Fentanyl
Noel, M., Abbs, E., Suen, L. W., Samuel, L., Dobbins, S. K., Geier, M., & Soran, C. S. (2023) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001154 · Cited by 23
Treatment initiation strategies for syringe exchange referrals to methadone maintenance: A randomized clinical trial
KIDORF, M. S., Brooner, R. K., Leoutsakos, J., & Peirce, J. M. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.03.009 · Cited by 22
Representation of adverse childhood experiences is associated with lower public stigma towards people who use drugs: an exploratory experimental study
Sumnall, H. R., Hamilton, I., Atkinson, A. M., Montgomery, C., & Gage, S. H. (2020) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2020.1820450 · Cited by 22
“This is of particular importance because problem substance use is associated with significant disease burden (Degenhardt et al., 2013, 2016), and early treatment entry is protective against morbidity and mortality (Hickman et al., 2018; Pierce et al., 2016; Platt et al., 2017; Sordo et al., 2017).”
Background
Changes in Buprenorphine Treatment After Medicaid Expansion
Olfson, M., Zhang, V., King, M. D., & Mojtabai, R. (2021) · Psychiatric Services · doi:10.1176/appi.ps.202000491 · Cited by 22
Facility Attractiveness and Social Vulnerability Impacts on Spatial Accessibility to Opioid Treatment Programs in South Carolina
Bozorgi, P., Eberth, J. M., Eidson, J. P., & Porter, D. E. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18084246 · Cited by 21
“Studies show that using these medications reduces the risk of overdose and opioid-related mortality [4,5].”
Perioperative Management of Buprenorphine/Naloxone in a Large, National Health Care System: a Retrospective Cohort Study
Wyse, J. J. B., Herreid-O’Neill, A., Dougherty, J., Shull, S., Mackey, K., Priest, K. C., Englander, H. L., Thoma, J., & Lovejoy, T. I. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07118-4 · Cited by 21
The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001–2018: Findings from the OATS retrospective linkage study
Jones, N. R., Hickman, M., Nielsen, S., Larney, S., Dobbins, T., Ali, R. L., & Degenhardt, L. J. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109464 · Cited by 21
Opioid Use Disorder, Sleep Deficiency, and Ventilatory Control: Bidirectional Mechanisms and Therapeutic Targets
Eckert, D. J., & Yaggi, H. K. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202108-2014ci · Cited by 24
Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians
Booty, M. D., Harp, K. L. H., Batty, E. J., Knudsen, H. K., Staton, M., & Oser, C. B. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209051 · Cited by 21
Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes
Bovell-Ammon, B. J., Yan, S., Dunn, D., Evans, E., Friedmann, P. D., Walley, A. Y., & Larochelle, M. R. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.2732 · Cited by 21
Prevalent Misconceptions About Opioid Use Disorders in the United States Produce Failed Policy and Public Health Responses
Heimer, R., Hawk, K. F., & Vermund, S. H. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy977 · Cited by 23
“21% of that for individuals not in treatment, and for those in buprenorphine treatment the risk is 30% of that for individuals not in treatment [62].”
Background
Opioid-related deaths and previous care for drug use and pain relief in Sweden
Fugelstad, A., Thiblin, I., Johansson, L. A., Ågren, G., & Sidorchuk, A. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.04.022 · Cited by 21
Supervised Injection Facility Utilization Patterns: A Prospective Cohort Study in Vancouver, Canada
Kennedy, M. C., Klassen, D. C., Dong, H., Milloy, M.-J. S., Hayashi, K., & Kerr, T. H. (2019) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2019.04.024 · Cited by 21
“It’s way more than just writing a prescription”: A qualitative study of preferences for integrated versus non-integrated treatment models among individuals with opioid use disorder
Saunders, E. C., Moore, S. K., Walsh, O., Metcalf, S. A., Budney, A. J., Cavazos‐Rehg, P. A., Scherer, E. A., & Marsch, L. A. (2021) · Addiction Science & Clinical Practice · doi:10.1186/s13722-021-00213-1 · Cited by 21
“We'll be able to take care of ourselves” – A qualitative study of client attitudes toward implementing buprenorphine treatment at syringe services programs
Frost, T., Deutsch, S., Brown, S., Lemien, E., Cunningham, C. O., & Fox, A. D. (2021) · Substance Abuse · doi:10.1080/08897077.2021.1901173 · Cited by 21
Linking Opioid-Overdose Data to Human Services and Criminal Justice Data: Opportunities for Intervention
Hacker, K. A., Jones, L. D., Brink, L. L., Wilson, A., Cherna, M., Dalton, E., & Hulsey, E. G. (2018) · Public Health Reports · doi:10.1177/0033354918803938 · Cited by 20
Risk assessment of using off‐label morphine sulfate in a population‐based retrospective cohort of opioid‐dependent patients
Bertin, C., Delorme, J., Riquelme, M., Peyrière, H., Brousse, G., Eschalier, A., Ardid, D., Chenaf, C., & Authier, N. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14082 · Cited by 20
The Use of the Methadone/Metabolite Ratio (MMR) to Identify an Individual Metabolic Phenotype and Assess Risks of Poor Response and Adverse Effects: Towards Scientific Methadone Dosing
McCarthy, J. J., Graas, J. E., Leamon, M. H., Ward, C. C., Vasti, E. J., & Fassbender, C. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000620 · Cited by 20
A Resident‐Led Intervention to Increase Initiation of Buprenorphine Maintenance for Hospitalized Patients With Opioid Use Disorder
Thakrar, A. P., Furfaro, D. M., Keller, S. C., Graddy, R., Buresh, M. E., & Feldman, L. S. (2021) · Journal of Hospital Medicine · doi:10.12788/jhm.3544 · Cited by 20
Toward a Typology of Office-based Buprenorphine Treatment Laws: Themes From a Review of State Laws
Andraka‐Christou, B., Gordon, A. J., Bouskill, K., Smart, R., Golan, O. K., Golan, M., Totaram, R., & Stein, B. D. (2021) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000863 · Cited by 20
An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders
Mintz, C. M., Presnall, N. J., Xu, K. Y., Hartz, S. M., Sahrmann, J. M., Bierut, L. J., & Grucza, R. A. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108886 · Cited by 21
A meta-analysis on the effects of incarceration-based opioid substitution treatment
Boksán, K., Dechant, M., Weiss, M., Hellwig, A., & Stemmler, M. P. (2022) · Medicine Science and the Law · doi:10.1177/00258024221118971 · Cited by 20
Characteristics and context of fentanyl test strip use among syringe service clients in southern Wisconsin
Tilhou, A. S., Birstler, J., Baltes, A., Salisbury‐Afshar, E., Malicki, J., Chen, G., & Brown, R. (2022) · Harm Reduction Journal · doi:10.1186/s12954-022-00720-7 · Cited by 23
“Treatment with medications for opioid use disorder (OUD) reduces opioid overdose mortality [5, 6].”
Background
The impact of recreational cannabis markets on motor vehicle accident, suicide, and opioid overdose fatalities
Marinello, S., & Powell, L. M. (2023) · Social Science & Medicine · doi:10.1016/j.socscimed.2023.115680 · Cited by 20
The importance of buprenorphine research in the opioid crisis
Pendergrass, S. A., Crist, R. C., Jones, L. K., Hoch, J. R., & Berrettini, W. H. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0329-5 · Cited by 21
A national case fatality study of drugs taken in intentional overdose
Daly, C., Griffin, E., Corcoran, P. E., Webb, R. T., Ashcroft, D. M., Perry, I. J., & Arensman, E. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.102609 · Cited by 22
Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017
Vold, J. H., Skurtveit, S. O., Aas, C. F., Chalabianloo, F., Kloster, P. S., Johansson, K. A., & Fadnes, L. T. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-05195-5 · Cited by 20

Authors: Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R.
Affiliations: Universidad Complutense de Madrid (ES)
Instituto de Salud Carlos III (ES)
The University of Melbourne (AU)
European Monitoring Centre for Drugs and Drug Addiction (PT)
Corresponding author: Barrio, Gregorio
ORCID: Sordo, Luis
Barrio, Gregorio
Degenhardt, Louisa
Wiessing, Lucas
Ferri, Marica
Venue: BMJ
Publisher: BMJ
Published: 2017-04-26
Volume: 357
Pages: j1550
ISSN: 1756-1833 (ISSN-L)
0959-8138
DOI: 10.1136/bmj.j1550
PMC: PMC5421454
OpenAlex: W2608446001
Cited by: 1,816
References: 76
Citations by year: 2026: 156 · 2025: 194 · 2024: 201 · 2023: 239 · 2022: 228 · 2021: 261 · 2020: 213 · 2019: 187 · 2018: 99 · 2017: 32
FWCI: 23.58
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc
www.bmj.org/licenses/tdm/1.0/terms-and-conditions.html (tdm)
Locations: BMJ (publishedVersion, cc-by-nc)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
PubMed Central (publishedVersion, cc-by-nc)
PubMed (publishedVersion)
LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
HighWire Press Open Archive (submittedVersion)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
Keywords: opioid substitution therapy, methadone, buprenorphine, opioid use disorder, all-cause mortality, drug overdose deaths, treatment retention, treatment discontinuation, harm reduction, opioid antagonists
MeSH terms: Buprenorphine, Humans, Methadone, Opioid-Related Disorders, Narcotics, Risk, Opiate Substitution Treatment, Drug Overdose

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks